Arginetix
Founded Year
2007Stage
Merger | MergedTotal Raised
$10.75MLatest Arginetix News
Dec 1, 2016
Arginetix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 13:49 EST 1 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Arginetix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Arginetix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Arginetix, Inc. since January 2007. Key Findings Provides intelligence on Arginetix, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Arginetix, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Arginetix, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Arginetix, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
When was Arginetix founded?
Arginetix was founded in 2007.
Where is Arginetix's headquarters?
Arginetix's headquarters is located at 2330 West Joppa Road, Lutherville.
What is Arginetix's latest funding round?
Arginetix's latest funding round is Merger.
How much did Arginetix raise?
Arginetix raised a total of $10.75M.
Who are the investors of Arginetix?
Investors of Arginetix include Corridor Pharmaceuticals, MedImmune Ventures, Quaker BioVentures, Red Abbey Venture Partners, Acidophil and 3 more.
Who are Arginetix's competitors?
Competitors of Arginetix include CVRx, Viamet Pharmaceuticals, Tolera Therapeutics, Anthera Pharmaceuticals, Spiration and 13 more.
You May Also Like
Asterion is a manufacturer of analog semiconductors.
Ash Access Technology is developing and commercializing products that address high unmet need in the area of vascular access-related complications with a focus on infectious disease therapies and device performance.
TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.
Antipodean is a pharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's Disease and Friedreich's Ataxia that are associated with mitochondrial dysfunction.
Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.
Alacrity Biosciences is a biopharmaceutical company focused on acquiring, developing and commercializing therapeutics to treat ophthalmic diseases that threaten vision and reduce patient quality of life.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.